6,846
Views
41
CrossRef citations to date
0
Altmetric
Clinical Studies

Clinicopathological study of originally non-lupus “full-house” nephropathy

&
Pages 1025-1030 | Received 29 Mar 2010, Accepted 19 Jul 2010, Published online: 23 Sep 2010

REFERENCES

  • Berden JH. Lupus nephritis. Kidney Int. 1997;52:538–558.
  • Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10: 413–424.
  • Tan EM, Cohen AS, Fries JF, The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–1277.
  • Gianviti A, Barsotti P, Barbera V, Faraggiana T, Rizzoni G. Delayed onset of systemic lupus erythematosus in patients with “full-house” nephropathy. Pediatr Nephrol. 1999;13: 683–687.
  • Baskin E, Agras PI, Menekse N, Ozdemir H, Cengiz N. Full-house nephropathy in a patient with negative serology for lupus. Rheumatol Int. 2007;27:281–284.
  • Miura M, Tomino Y, Nomoto Y, IgA nephropathy with “full house” immunofluorescence. Am J Clin Pathol. 1983; 79:273.
  • Smet AD, Kuypers D, Evenepoel P, “Full house” positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. Nephrol Dial Transplant. 2001;16:2258–2262.
  • Lee LC, Lam KK, Lee CT, Chen JB, Tsai TH, Huang SC. “Full house” proliferative glomerulonephritis: An unreported presentation of subacute infective endocarditis. J Nephrol. 2007;20:745–749.
  • Jennette JC, Hipp CG. C1q nephropathy: A distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985;6:103–110.
  • Vizjak A, Ferluga D, Rozic M, Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol. 2008;19:2237–2244.
  • Haas M, Racusen LC, Bagnasco SM. IgA-dominant postinfectious glomerulonephritis: A report of 13 cases with common ultrastructural features. Hum Pathol. 2008; 39:1309–1316.
  • Koyama A, Kobayashi M, Yamaguchi N, Glomerulonephritis associated with MRSA infection: A possible role of bacterial superantigen. Kidney Int. 1995;47:207–216.
  • Chen PC, Wang CR, Liu MF, Chen FF, Liang CC. Correlation between the renal C1q deposition and serum anti-C1q antibody: A potential role of anti-C1q antibody in lupus nephritis. Asian Pac J Allergy Immunol. 2002;20:223–227.
  • Kozyro I, Korosteleva L, Chernoshej D, Danner D, Sukalo A, Trendelenburg M. Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clin Immunol. 2008;128:409–414.
  • Cairns SA, Acheson EJ, Corbett CL, The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis. Postgrad Med J. 1979;55:723–727.
  • Jones E, Magil A. Nonsystemic mesangiopathic glomerulonephritis with “full house” immunofluorescence. Pathological and clinical observation in five patients. Am J Clin Pathol. 1982;78:29–34.
  • Adu D, Williams DG, Taube D, Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. Q J Med. 1983; 52:471–487.
  • Enriquez JL, Rajaraman S, Kalia A, Brouhard BH, Travis LB. Isolated antinuclear antibody-negative lupus nephropathy in young children. Child Nephrol Urol. 1988;9:340–346.
  • Sharman A, Furness P, Feehally J. Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant. 2004;19: 1420–1426.
  • Weening JJ, D'Agati VD, Schwartz MM, The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–250.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.